Journal of Cancer Research and Clinical Oncology最新文献

{"title":"Correction: Small cell osteosarcoma in gnathic bones in the maxilla: case report in a pediatric patient.","authors":"Tayná Souza Gomes da Silva, Ilan Hudson Gomes de Santana, Helder Domiciano Dantas Martins, Raabe Carine Ferreira de Melo, Paulo Rogério Ferreti Bonan","doi":"10.1007/s00432-025-06143-8","DOIUrl":"10.1007/s00432-025-06143-8","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"114"},"PeriodicalIF":2.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing and validating a prognostic disulfidptosis-related signature for glioblastoma: predicting radioresistance and synergestic effect with immunotherapy.","authors":"Chen Chen, Peixin Tan, Wenqing Feng, Yuan Lei, Shushu Hu, Dehuan Xie, Yantan Liu, Chen Ren, Shasha Du","doi":"10.1007/s00432-025-06159-0","DOIUrl":"10.1007/s00432-025-06159-0","url":null,"abstract":"<p><strong>Background: </strong>Programmed cell death (PCD) modulated radioresistance is one of the predominant causes of treatment failure in glioblastoma (GBM). Disulfidptosis, a newly discovered form of PCD, plays a crucial role in GBM progression. However, the association among disulfidptosis, radiosensitivity and radiotherapy (RT) in GBM remain unclear.</p><p><strong>Methods: </strong>We systematically analyzed disulfidptosis-related genes in 1075 GBM patients and constructed a disulfidptosis-related gene signature (DRS). Correlations among the DRS, patient prognosis and immune microenvironment were fully explored. The effects of DRS and EFEMP2 on radiotherapy efficacy were investigated via single cell sequencing analysis and validated via in vitro and in vivo experiments.</p><p><strong>Results: </strong>The DRS was identified as a robust and independent prognostic biomarker for GBM by multivariate Cox regression analysis, receiver operating characteristic (ROC) curve analysis and decision curve analysis (DCA) in multiple cohorts. High DRS is characterized by radioresistance, and EFEMP2 was proven to be the key gene involved in this process by single cell sequencing analysis, CCK-8 assay and a clonogenic survival assay. In high-DRS patients, the cancer-immunity cycle is attenuated because the antitumor cytotoxicity of CD8+ T cells is inhibited by immune checkpoints. Preclinically, the overexpression of EFEMP2 induced radioresistance and enhancing the efficacy of programmed cell death ligand-1 (PD-L1) blockade in GL261-bearing mice. The combination of irradiation and anti-PD-L1 therapy had a synergistic effect on GBM murine models in which EFEMP2 was overexpressed.</p><p><strong>Conclusion: </strong>Our study bioinformatically and experimentally reveals the molecular landscape of disulfidptosis in GBM, develops a predictive signature for predicting prognosis as well as radioresistance, and provides a synergistic treatment that combines radiotherapy with immunotherapy for radioresistant GBM patients with high DRS or EFEMP2 expression.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"112"},"PeriodicalIF":2.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11919952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated platelet distribution width and diabetes may serve as preoperative predictors of microvascular invasion in primary hepatocellular carcinoma.","authors":"Ling Wang, Liu Jun, Jia Jian'an, Rao Chunmei, Jiang Yuhuan, Liu Peng, Li Huiming","doi":"10.1007/s00432-025-06157-2","DOIUrl":"10.1007/s00432-025-06157-2","url":null,"abstract":"<p><strong>Background and objective: </strong>Hepatocellular carcinoma (HCC) is one of the malignancies with increasing incidence globally, and microvascular invasion (MVI) is a crucial determinant of prognosis in patients. This study aimed to investigate platelet distribution width (PDW) and diabetes mellitus as indicators for predicting preoperative MVI in HCC, providing more accurate predictive tools for clinicians to guide treatment strategies and improve patient survival and quality of life.</p><p><strong>Methods: </strong>A retrospective study was conducted, including 1357 patients who underwent hepatectomy for HCC between January 2008 and December 2014 at the Eastern Hepatobiliary Surgery Hospital in China. Clinical, pathological, and radiological data, including PDW and diabetes status, were collected. Univariate and multivariate logistic regression analyses were performed to identify risk factors for MVI and establish a predictive model. The predictive performance of the model was evaluated through nomograms and internal validation.</p><p><strong>Results: </strong>Univariate analysis revealed significant associations between MVI and diabetes mellitus, presence of liver cirrhosis, prealbumin level, tumor diameter, number of tumors, HBV DNA viral load > 10⁴, and PDW ≥ 17. Multivariate logistic regression analysis identified diabetes mellitus, liver cirrhosis, prealbumin level, tumor diameter, number of tumors, HBV DNA viral load > 10⁴, and PDW ≥ 17 as independent risk factors for MVI. Based on these findings, a predictive model was established, demonstrating high predictive accuracy and stability in both the training and validation cohorts.</p><p><strong>Conclusion: </strong>This study confirmed PDW and diabetes mellitus as reliable indicators for predicting preoperative MVI in HCC and established a corresponding predictive model. Future research should further explore the underlying mechanisms and enhance clinical validation to advance the field of HCC treatment.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"111"},"PeriodicalIF":2.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel strategy for sorafenib-resistant hepatocellular carcinoma: autotaxin Inhibition by PF-8380.","authors":"Bong Jun Kwak, Jung Hyun Park, Ok-Hee Kim, Dosang Lee, Tae Ho Hong, Sang Chul Lee, Kee-Hwan Kim, Ho Joong Choi, Say-June Kim","doi":"10.1007/s00432-025-06156-3","DOIUrl":"10.1007/s00432-025-06156-3","url":null,"abstract":"<p><p>By inhibiting the conversion of lysophosphatidylcholine into lysophosphatidic acid, a process pivotal to tumor progression, the autotaxin (ATX) inhibitor PF-8380 offers a new anticancer therapeutic strategy, distinct from the action mechanism of sorafenib. This study explored the potential anticancer effects of the PF-8380 on hepatocellular carcinoma (HCC) cells, especially sorafenib-resistant strains. The investigation included both in vitro and in vivo experiments to evaluate the impact of PF-8380 treatment on epithelial-mesenchymal transition (EMT) and autophagy markers. An orthotopic HCC model served as the in vivo platform. PF-8380 showed a significant reduction in cell viability in both sorafenib-susceptible and resistant HCC cells. It effectively altered EMT by increasing E-cadherin and reducing Snail levels, and inhibited autophagy, as indicated by changes in LC3 and p62 markers. These effects were consistently observed in the orthotopic HCC mouse model, reinforcing PF-8380's potential as a dual inhibitor of EMT and autophagy in HCC treatment. Our research indicates that PF-8380 could provide substantial therapeutic benefits in the treatment of HCC, even in cases resistant to sorafenib, primarily by suppressing both EMT and autophagy processes.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"110"},"PeriodicalIF":2.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906571/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telomere length and telomerase reverse transcriptase gene polymorphism as potential markers of complete chimerism and GvHD development after allogeneic haematopoietic stem cell transplantation.","authors":"Marta Dratwa-Kuzmin, Piotr Lacina, Barbara Wysoczanska, Dorota Kilinska, Jagoda Siemaszko, Malgorzata Sobczyk-Kruszelnicka, Wojciech Fidyk, Iwona Solarska, Barbara Nasiłowska-Adamska, Patrycja Skowronska, Maria Bieniaszewska, Agnieszka Tomaszewska, Grzegorz Basak, Sebastian Giebel, Katarzyna Bogunia-Kubik","doi":"10.1007/s00432-025-06160-7","DOIUrl":"10.1007/s00432-025-06160-7","url":null,"abstract":"<p><strong>Introduction: </strong>Telomerase reverse transcriptase (TERT) is a catalytic subunit of telomerase that maintains genome stability by maintaining telomere length (TL). The massive proliferation of donor cells in the recipient's body for engraftment results in accelerated telomere shortening. Genetic variability within the TERT gene affects telomerase activity, and was shown to influence of haematopoietic stem cell transplantation (HSCT) outcome. In the present study, we aimed to analyse the effect of recipient and donor TL and TERT single nucleotide polymorphism (SNP) on the occurrence of post-HSCT complications.</p><p><strong>Methods: </strong>Our study included 120 recipient-donor pairs. TERT promoter (TERTp) SNP (rs2853669) SNP variant was detected with the use of the LightSNiP typing assay employing real-time polymerase chain reaction (PCR) amplifications. Telomere length measurements were performed using qPCR test kits (ScienCell's Absolute Human Telomere Length Quantification qPCR Assay Kit [AHTLQ], Carlsbad, CA, USA).</p><p><strong>Results: </strong>The presence of TERTp rs2853669 T allele in the recipient was associated with a higher risk for acute graft-versus-host-disease (aGvHD) manifestation (p = 0.046) and a significantly shorter aGvHD-free survival (p = 0.041). The latter association was further confirmed in a Cox proportional hazards model (p = 0.043). However, no statistically significant association between telomere length and post-transplant complications was observed. Furthermore, we found that shorter TL characterized donors of patients with late complete chimerism at 180 day after HSCT (p = 0.011).</p><p><strong>Conclusion: </strong>Our results suggest that recipient allele TERTp rs2853669 T is a marker of unfavourable outcome in the context of aGvHD. Shorter TL in donors could be associated with later achievement of complete chimerism.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"109"},"PeriodicalIF":2.7,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11906511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143624661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should lymphadenectomy be recommended in radical surgery of intrahepatic cholangiocarcinoma patients? A retrospective study.","authors":"Ruoyu Zhang, Dayong Cao, Min Yang, Jiajun Zhang, Feng Ye, Ning Huang, Mei Liu, Bo Chen, Liming Wang","doi":"10.1007/s00432-025-06148-3","DOIUrl":"10.1007/s00432-025-06148-3","url":null,"abstract":"<p><strong>Purpose: </strong>Intrahepatic cholangiocarcinoma (ICC) is an extremely deadly cancer with high recurrence incidence, particularly in patients with lymph node metastasis (LNM). The necessity of lymphadenectomy including lymph node biology (LNB) and dissection (LND) during ICC radical surgery remains debate.</p><p><strong>Methods: </strong>We retrospectively analyzed the patients diagnosed with ICC and underwent radical surgery at the Cancer Hospital of the Chinese Academy of Medical Sciences from 2012 to 2023.</p><p><strong>Results: </strong>A total of 308 ICC patients were involved in this study. pLNM⁺ group had poorer OS (P < 0.0001) and poorer DFS (P < 0.0001) compared with pLNM^- group. Compared to the LN^- group, LN⁺ group exhibited worse OS (P = 0.038) and worse DFS (P = 0.003). After PSM and IPTW, compared with LN^- group, LNB exhibited longer operation time (IPTW: P = 0.0024) and longer hospitalization days (IPTW: P = 0.0112) with no significant differences in complications, DFS, and OS. Compared with LN^- group, LND group had no better DFS and OS, only more complications (IPTW: P = 0.0191), longer operation time (all P < 0.001), higher risk of bleeding (all P < 0.05), transfusion (IPTW: P = 0.014) and longer hospitalization days (IPTW: P = 0.0044). Compared with LNB group, LND had longer operation time (P = 0.0227), higher risk of bleeding (P = 0.017) and transfusion (P = 0.0321), and more postoperative complications (P = 0.0425), with no difference in DFS and OS.</p><p><strong>Conclusion: </strong>Lymphadenectomy does not necessarily provide long-term survival or recurrence benefits. LND only achieves the effect of LNB while negatively affects postoperative recovery without survival benefit for ICC patients. LNB can be performed for accurate pathological staging while not all patients may require LND based on their specific circumstances.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"107"},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma.","authors":"Guichun Huang, Longbang Chen","doi":"10.1007/s00432-025-06103-2","DOIUrl":"10.1007/s00432-025-06103-2","url":null,"abstract":"","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"108"},"PeriodicalIF":2.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11903533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143615620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic lymphocytic leukemia (CLL) screening and abnormality detection based on multi-layer fluorescence imaging signal enhancement and compensation.","authors":"Lemin Shi, Ping Gong, Mingye Li, Dianxin Song, Hao Zhang, Zhe Wang, Xin Feng","doi":"10.1007/s00432-025-06150-9","DOIUrl":"10.1007/s00432-025-06150-9","url":null,"abstract":"<p><strong>Purpose: </strong>Fluorescence in situ hybridization (FISH) plays a critical role in cancer screening but faces challenges in signal clarity and manual intervention. This study aims to enhance FISH signal clarity, improve screening efficiency, and reduce false negatives through an automated image acquisition and signal enhancement framework.</p><p><strong>Methods: </strong>An automated workflow was developed, integrating a dynamic signal enhancement method that optimizes global and local features. An improved Cycle-GAN network was introduced, incorporating residual connections and layer-wise supervision to accurately model and compensate for complex signal characteristics. Key metrics such as signal brightness, edge gradients, contrast improvement index (CII), and structural similarity index (SSIM) were used to evaluate performance.</p><p><strong>Results: </strong>The proposed method increased weak signal brightness by 49.02%, edge gradients by 48.61%, and CII by 32.52%. The SSIM reached 0.996, indicating high fidelity to original signals.</p><p><strong>Conclusion: </strong>Visual analysis demonstrated clearer, more continuous, and uniform fluorescence signals, effectively mitigating fragmentation and uneven distribution. These improvements reduced false negatives and enhanced genomic abnormality detection accuracy. The proposed method significantly improves FISH signal clarity and stability, providing reliable support for cancer screening, genomic abnormality detection, molecular typing, prognosis evaluation, and targeted treatment planning.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"106"},"PeriodicalIF":2.7,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bone mineral density as potential individual prognostic biomarker in patients with neurosurgically treated spinal metastasis.","authors":"H Asoglu, T Lampmann, M Jaber, L Khalafov, J Dittmer, I Ilic, G H Gielen, M Toma, H Vatter, Z Bendella, M Schneider, C Schmeel, M Hamed, M Banat","doi":"10.1007/s00432-025-06142-9","DOIUrl":"10.1007/s00432-025-06142-9","url":null,"abstract":"<p><strong>Introduction: </strong>Bone mineral density (BMD) plays a crucial role in diagnosing and treating various systemic chronic diseases. Patients with multiple or singular spinal metastasis (SM) are typically in advanced stages of systemic cancer, often leading to significant alterations in BMD. The present study investigated the prognostic value of perioperative Hounsfield units (HU) as a surrogate independent marker for estimated BMD in patients with SM after surgical treatment (ST).</p><p><strong>Methods: </strong>HU values, serving as a surrogate for estimated BMD, were measured from circular regions of interest (ROIs) in the spine -first lumbar vertebra (L1)- from routine preoperative staging computed tomography (CT) scans in 187 patients after ST. The estimated BMD was stratified into pathologic and physiologic values and correlated with survival parameters in our cohorts.</p><p><strong>Results: </strong>Median L1 BMD of 92 patients (49%) with pathologic BMD was 79.5 HU (IQR 67.25-93.5) compared to 145 HU (IQR 123-166) for 95 patients (51%) with physiologic BMD (p ≤ 0.001). Patients with pathological BMD exhibited a median overall survival of 8 months compared to 12.2 months in patients with physiologic BMD (p = 0.006). Multivariable analysis revealed pathologic BMD as an independent negative prognostic predictor for increased 1 year mortality (AUC: 0.637, 95% CI: 0.556-0.718; p = 0.001).</p><p><strong>Conclusions: </strong>The present study demonstrates that decreased perioperative BMD values, as derived from HU measurements, may represent a previously unrecognized negative prognostic factor in patients of SM after ST. The estimated perioperative BMD could emerge as an individualized, readily available potential biomarker for prognostic, treatment, and discussion of affected patients with SM.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"105"},"PeriodicalIF":2.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11893684/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143597005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of LIMK1 as a biomarker in clear cell renal cell carcinoma: from data mining to validation.","authors":"Yifei Li, Congcong Fan, Feng Jiang, Jingnan Zhang, Yanzhen Li, Yanjie Jiang, Rui Zhang, Zhixian Yu, Siqi Wang","doi":"10.1007/s00432-025-06146-5","DOIUrl":"10.1007/s00432-025-06146-5","url":null,"abstract":"<p><strong>Purpose: </strong>Clear cell renal cell carcinoma (ccRCC) is one of the most common types of renal cancer. LIM kinase 1 (LIMK1) reportedly plays an important role in tumorigenesis. However, the involvement of LIMK1 in the progression of ccRCC remains ambiguous.</p><p><strong>Methods: </strong>Based on the TCGA and CPTAC databases, the expression of LIMK1 in ccRCC was evaluated. In the TCGA-ccRCC cohort, the relationships between LIMK1 and immune cell infiltration as well as immune checkpoints were assessed. The high expression of LIMK1 in ccRCC was verified by qRT-PCR in four RCC cell lines. Immunohistochemistry was used to evaluate the expression of LIMK1 in clinical samples. The association between LIMK1 expression and survival prognosis was explored via Kaplan-Meier survival curve in the TCGA-ccRCC and local cohorts. The effects of LIMK1 knockdown on the proliferation, migration, and invasion abilities of RCC cells were evaluated via colony, CCK-8, wound healing, and Transwell assays.</p><p><strong>Results: </strong>Elevated expression level of LIMK1 was found in the TCGA-ccRCC cohort and was confirmed in RCC cell lines and clinical samples. Up-regulation of LIMK1 was found to be correlated with poor prognosis in TCGA-ccRCC and external cohorts. In addition, high-LIMK1 was associated with clinicopathological stage, immune cell infiltration and immune checkpoint in ccRCC. Importantly, knockdown of LIMK1 diminished the capability of proliferation, migration, and invasion in RCC cells.</p><p><strong>Conclusion: </strong>LIMK1 may serve as a promising diagnostic and prognostic biomarker of ccRCC.</p>","PeriodicalId":15118,"journal":{"name":"Journal of Cancer Research and Clinical Oncology","volume":"151 3","pages":"104"},"PeriodicalIF":2.7,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11890329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143582286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}